SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
SAB Biotherapeutics announced that it will present clinical data on SAB-142, its lead immunotherapy candidate for newly diagnosed Stage 3 type 1 diabetes, at the American Diabetes Association's 2026 Scientific Sessions and the Federation of Clinical Immunology Societies 2026 Annual Meeting. The presentations will showcase SAB-142's safety, pharmaco…